Clinical Trial

Safety and Efficacy of VDPHL01 in Males With AGA

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-06; most recent amendment 2026-02-11.
Status change: Recruiting → Active, Not Recruiting 2026-02-11
Trial Details
NCT Number NCT06972264
Lead Sponsor Veradermics, Inc.
Conditions Androgenetic Alopecia, AGA, Male Pattern Baldness
Enrollment 480 participants
Start Date 2025-03-11
Primary Completion 2026-12 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-02-12